Your session is about to expire
← Back to Search
EGF816 + Gefitinib for Lung Cancer
Study Summary
This trial is testing whether the combination of these drugs is more effective in treating EGFR mutation-positive lung cancer than either drug alone.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
What is the regulatory status of Gefitinib?
"The safety rating of Gefitinib is a 2 since this trial, which assesses its efficacy, is only in the second phase. Nevertheless, there have been some studies verifying its security."
Is there space in this trial for more participants?
"Per the information on clinicaltrials.gov, this research endeavour is currently not recruiting participants. Initially posted in October 2017 and last updated in January 2022, there are presently no vacancies for this study; however, 1656 other medical investigations remain open to enrolment at this time."
What is the capacity of participants for this investigation?
"Unfortunately, this clinical trial is not presently accepting enrollees. It was initially advertised on October 31st 2017 and edited as recently as January 21st 2022. Alternatively, researchers are currently recruiting 1628 participants to test treatments for lung cancer and 28 people for Gefitinib studies."
Have there been previous experiments with Gefitinib to assess its efficacy?
"At the moment, there are 28 ongoing studies assessing Gefitinib. Of these trials, 10 have reached Phase 3 and most of them are based in Chuo-Ku, Tokyo. However, a total of 539 sites across the world are conducting research related to this medication."
Share this study with friends
Copy Link
Messenger